FDA approves Voraxaze from BTG for ultra-rare indication
This article was originally published in Scrip
The US FDA has granted approval for BTG's biologics license application for Voraxaze (glucarpidase) to treat high dose methotrexate toxicity, an ultra-rare indication with only 300 sufferers in the US per year.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.